Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the
following statement regarding the conclusion of the European Medicines
Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)
review of GLP-1, or incretin-based, therapies, including sitagliptin.
Language:
English
Contact:
MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, 908-423-4465
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Incretin Therapy | Januvia | Merck | Pharmaceuticals